| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ... The Lancet 389 (10088), 2492-2502, 2017 | 4032 | 2017 |
| A community effort to assess and improve drug sensitivity prediction algorithms JC Costello, LM Heiser, E Georgii, M Gönen, MP Menden, NJ Wang, ... Nature biotechnology 32 (12), 1202-1212, 2014 | 772 | 2014 |
| NRF2 regulates serine biosynthesis in non–small cell lung cancer GM DeNicola, PH Chen, E Mullarky, JA Sudderth, Z Hu, D Wu, H Tang, ... Nature genetics 47 (12), 1475-1481, 2015 | 664 | 2015 |
| 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth Q Wu, T Ishikawa, R Sirianni, H Tang, JG McDonald, IS Yuhanna, ... Cell reports 5 (3), 637-645, 2013 | 364 | 2013 |
| A community computational challenge to predict the activity of pairs of compounds M Bansal, J Yang, C Karan, MP Menden, JC Costello, H Tang, G Xiao, ... Nature biotechnology 32 (12), 1213-1222, 2014 | 322 | 2014 |
| A 12-gene set predicts survival benefits from adjuvant chemotherapy in non–small cell lung cancer patients H Tang, G Xiao, C Behrens, J Schiller, J Allen, CW Chow, M Suraokar, ... Clinical cancer research 19 (6), 1577-1586, 2013 | 318 | 2013 |
| Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma B Sangro, I Melero, S Wadhawan, RS Finn, GK Abou-Alfa, AL Cheng, ... Journal of hepatology 73 (6), 1460-1469, 2020 | 296 | 2020 |
| Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations M Sato, JE Larsen, W Lee, H Sun, DS Shames, MP Dalvi, RD Ramirez, ... Molecular cancer research 11 (6), 638-650, 2013 | 209 | 2013 |
| An expression signature as an aid to the histologic classification of non–small cell lung cancer L Girard, J Rodriguez-Canales, C Behrens, DM Thompson, IW Botros, ... Clinical Cancer Research 22 (19), 4880-4889, 2016 | 172 | 2016 |
| Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition AS Laino, D Woods, M Vassallo, X Qian, H Tang, M Wind-Rotolo, J Weber Journal for immunotherapy of cancer 8 (1), 2020 | 154 | 2020 |
| Use of in Vitro HTS-Derived Concentration–Response Data as Biological Descriptors Improves the Accuracy of QSAR Models of in Vivo Toxicity A Sedykh, H Zhu, H Tang, L Zhang, A Richard, I Rusyn, A Tropsha Environmental health perspectives 119 (3), 364-370, 2011 | 128 | 2011 |
| Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation H Tang, XS Wang, XP Huang, BL Roth, KV Butler, AP Kozikowski, M Jung, ... Journal of chemical information and modeling 49 (2), 461-476, 2009 | 121 | 2009 |
| Prediction of human population responses to toxic compounds by a collaborative competition F Eduati, LM Mangravite, T Wang, H Tang, JC Bare, R Huang, T Norman, ... Nature biotechnology 33 (9), 933-940, 2015 | 119 | 2015 |
| Decreased BECN1 mRNA expression in human breast cancer is associated with estrogen receptor-negative subtypes and poor prognosis H Tang, S Sebti, R Titone, Y Zhou, C Isidoro, TS Ross, H Hibshoosh, ... EBioMedicine 2 (3), 255-263, 2015 | 117 | 2015 |
| LCE: an open web portal to explore gene expression and clinical associations in lung cancer L Cai, SY Lin, L Girard, Y Zhou, L Yang, B Ci, Q Zhou, D Luo, B Yao, ... Oncogene 38 (14), 2551-2564, 2019 | 92 | 2019 |
| Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis SK Sieberts, F Zhu, J García-García, E Stahl, A Pratap, G Pandey, ... Nature communications 7 (1), 12460, 2016 | 92 | 2016 |
| Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial JS Weber, M Del Vecchio, M Mandala, H Gogas, AM Arance, S Dalle, ... Annals of Oncology 30, v533-v534, 2019 | 86 | 2019 |
| TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma FS Hodi, JD Wolchok, D Schadendorf, J Larkin, GV Long, X Qian, A Saci, ... Cancer Immunology Research 9 (10), 1202-1213, 2021 | 84 | 2021 |
| Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915) JS Weber, D Schadendorf, M Del Vecchio, J Larkin, V Atkinson, ... Journal of Clinical Oncology 41 (3), 517-527, 2023 | 83 | 2023 |
| Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142. MJ Overman, S Lonardi, F Leone, RS McDermott, MA Morse, KYM Wong, ... Journal of Clinical Oncology 35 (4_suppl), 519-519, 2017 | 83 | 2017 |
